May 2009 Volume 5 Number 5
Visit Nature Reviews Rheumatology online to browse the journal.
Now available at
http://links.ealert.nature.com/ctt?kn=60&m=32688512&r=MTc2NDQ4MTc5OAS2&b=2&j=NDgxNzMyMTAS1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access
to Nature Reviews Rheumatology online. To purchase a subscription,
please visit:
http://links.ealert.nature.com/ctt?kn=1&m=32688512&r=MTc2NDQ4MTc5OAS2&b=2&j=NDgxNzMyMTAS1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=37&m=32688512&r=MTc2NDQ4MTc5OAS2&b=2&j=NDgxNzMyMTAS1&mt=1&rt=0
*********************************************************************
Nature Reviews Rheumatology Impact Factor: 3.812*
(*Journal Citation Reports, Thomson, 2005)
*********************************************************************
"Officially endorsed by the Asia Pacific League of Associations for
Rheumatology"
=========================== ADVERTISEMENT ===========================
Nature Reviews Goes Clinical!
In April 2009, Nature Clinical Practice Rheumatology was completely
redesigned and became Nature Reviews Rheumatology, bringing all the
qualities of the top-ranked* life science review series to the clinical
sciences.
For more information visit:
http://links.ealert.nature.com/ctt?kn=125&m=32688512&r=MTc2NDQ4MTc5OAS2&b=2&j=NDgxNzMyMTAS1&mt=1&rt=0
*2007 Journal Citation Report (Thomson Reuters, 2008)
=====================================================================
----------------------
RESEARCH HIGHLIGHTS
----------------------
Autoimmunity: Preventing recurrent pregnancy loss: time to rethink the
standard of care?
p233 | doi:10.1038/nrrheum.2009.66
http://links.ealert.nature.com/ctt?kn=74&m=32688512&r=MTc2NDQ4MTc5OAS2&b=2&j=NDgxNzMyMTAS1&mt=1&rt=0
Osteoarthritis: Autologous cartilage grafts for OA: stable 4 years on
p234 | doi:10.1038/nrrheum.2009.69
http://links.ealert.nature.com/ctt?kn=101&m=32688512&r=MTc2NDQ4MTc5OAS2&b=2&j=NDgxNzMyMTAS1&mt=1&rt=0
IN BRIEF
Pediatric rheumatology | Therapy | Crystal arthritis | Rheumatoid arthritis
p234 | doi:10.1038/nrrheum.2009.74
http://links.ealert.nature.com/ctt?kn=30&m=32688512&r=MTc2NDQ4MTc5OAS2&b=2&j=NDgxNzMyMTAS1&mt=1&rt=0
Gene therapy: Exosomal therapy for established arthritis
p235 | doi:10.1038/nrrheum.2009.33
http://links.ealert.nature.com/ctt?kn=98&m=32688512&r=MTc2NDQ4MTc5OAS2&b=2&j=NDgxNzMyMTAS1&mt=1&rt=0
Rheumatoid arthritis: Lack of telomerase causes telomere shortening in RA
p235 | doi:10.1038/nrrheum.2009.68
http://links.ealert.nature.com/ctt?kn=90&m=32688512&r=MTc2NDQ4MTc5OAS2&b=2&j=NDgxNzMyMTAS1&mt=1&rt=0
Imaging: Bye-bye biopsy?
p236 | doi:10.1038/nrrheum.2009.36
http://links.ealert.nature.com/ctt?kn=81&m=32688512&r=MTc2NDQ4MTc5OAS2&b=2&j=NDgxNzMyMTAS1&mt=1&rt=0
Vitamin C might lower gout risk
p236 | doi:10.1038/nrrheum.2009.78
http://links.ealert.nature.com/ctt?kn=130&m=32688512&r=MTc2NDQ4MTc5OAS2&b=2&j=NDgxNzMyMTAS1&mt=1&rt=0
Connective tissue diseases: Angiogenic clues to vascular injury in SSc
p237 | doi:10.1038/nrrheum.2009.65
http://links.ealert.nature.com/ctt?kn=134&m=32688512&r=MTc2NDQ4MTc5OAS2&b=2&j=NDgxNzMyMTAS1&mt=1&rt=0
IN BRIEF
Metabolic bone diseases | Autoimmunity | Therapy | Inflammation
p237 | doi:10.1038/nrrheum.2009.75
http://links.ealert.nature.com/ctt?kn=121&m=32688512&r=MTc2NDQ4MTc5OAS2&b=2&j=NDgxNzMyMTAS1&mt=1&rt=0
Therapy: Rethinking small molecules for RA
p238 | doi:10.1038/nrrheum.2009.34
http://links.ealert.nature.com/ctt?kn=124&m=32688512&r=MTc2NDQ4MTc5OAS2&b=2&j=NDgxNzMyMTAS1&mt=1&rt=0
Therapy: Drug duo increases therapeutic window
p238 | doi:10.1038/nrrheum.2009.38
http://links.ealert.nature.com/ctt?kn=22&m=32688512&r=MTc2NDQ4MTc5OAS2&b=2&j=NDgxNzMyMTAS1&mt=1&rt=0
Arthritis: IL-33: another candidate for arthritis
p239 | doi:10.1038/nrrheum.2009.70
http://links.ealert.nature.com/ctt?kn=24&m=32688512&r=MTc2NDQ4MTc5OAS2&b=2&j=NDgxNzMyMTAS1&mt=1&rt=0
Connective tissue diseases: Leflunomide: less toxic than standard therapy
for lupus nephritis?
p240 | doi:10.1038/nrrheum.2009.37
http://links.ealert.nature.com/ctt?kn=12&m=32688512&r=MTc2NDQ4MTc5OAS2&b=2&j=NDgxNzMyMTAS1&mt=1&rt=0
Connective tissue diseases: Kidney damage is a key predictor of mortality
in SLE
p240 | doi:10.1038/nrrheum.2009.67
http://links.ealert.nature.com/ctt?kn=66&m=32688512&r=MTc2NDQ4MTc5OAS2&b=2&j=NDgxNzMyMTAS1&mt=1&rt=0
----------------------
NEWS AND VIEWS
----------------------
Spondyloarthropathies: Targeted therapy for psoriatic arthritis
Dafna D. Gladman
p241 | doi:10.1038/nrrheum.2009.76
Tumor necrosis factor inhibitors are an effective treatment for psoriatic
arthritis, but no single agent is effective in all patients. Novel therapies
that target other cytokines have now been tested, with encouraging results.
http://links.ealert.nature.com/ctt?kn=92&m=32688512&r=MTc2NDQ4MTc5OAS2&b=2&j=NDgxNzMyMTAS1&mt=1&rt=0
Pain Management: Opioid guidelines: helpful for the rheumatologist?
Mary-Ann Fitzcharles and Yoram Shir
p242 | doi:10.1038/nrrheum.2009.63
Opioids are increasingly used for the treatment of chronic noncancer pain,
but this practice remains controversial. A new set of clinical
recommendations attempts to guide clinicians through the issues.
http://links.ealert.nature.com/ctt?kn=73&m=32688512&r=MTc2NDQ4MTc5OAS2&b=2&j=NDgxNzMyMTAS1&mt=1&rt=0
Autoimmunity: CTLA-4: a key protein in autoimmunity
Jagadeesh Bayry
p244 | doi:10.1038/nrrheum.2009.77
Studies performed during the past 2 years have provided a deeper
understanding into the role of CTLA-4, which is expressed on regulatory
T cells, in preventing autoimmunity, and also provide mechanistic insight
into protein-based therapeutics such as abatacept for rheumatic diseases.
http://links.ealert.nature.com/ctt?kn=79&m=32688512&r=MTc2NDQ4MTc5OAS2&b=2&j=NDgxNzMyMTAS1&mt=1&rt=0
Therapy: A local approach to Raynaud phenomenon
Ariane L. Herrick
p246 | doi:10.1038/nrrheum.2009.64
The current treatment options for Raynaud phenomenon are often ineffective
and can have undesirable adverse effects. Topical, or transdermal, treatments
that increase digital blood flow without systemic adverse effects are,
therefore, an attractive option. A novel topical nitroglycerin formulation
has shown promise in treating Raynaud attacks.
http://links.ealert.nature.com/ctt?kn=58&m=32688512&r=MTc2NDQ4MTc5OAS2&b=2&j=NDgxNzMyMTAS1&mt=1&rt=0
----------------------
REVIEWS
----------------------
Recurrent febrile syndromes-what a rheumatologist needs to know
Hal M. Hoffman and Anna Simon
p249 | doi:10.1038/nrrheum.2009.40
Recurrent febrile syndromes are rare autoinflammatory disorders characterized
by recurrent episodes of fever and systemic inflammation that present a
diagnostic challenge to rheumatologists. In this Review, the authors
outline the clinical features, pathophysiologic mechanisms, diagnostic
challenges, and therapeutic strategies for these syndromes.
Abstract: http://links.ealert.nature.com/ctt?kn=52&m=32688512&r=MTc2NDQ4MTc5OAS2&b=2&j=NDgxNzMyMTAS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=43&m=32688512&r=MTc2NDQ4MTc5OAS2&b=2&j=NDgxNzMyMTAS1&mt=1&rt=0
Gene-expression profiling in rheumatic disease: tools and therapeutic
potential
Jason W. Bauer, Hatice Bilgic and Emily C. Baechler
p257 | doi:10.1038/nrrheum.2009.50
Genomic technologies are becoming increasingly accessible to clinical
research laboratories. Gene-expression profiling is a powerful tool that
can be used for the identification of biomarkers, with potential widespread
clinical applications in rheumatic disease. These applications, together
with an overview of the latest technologies for gene-expression profiling,
are outlined in this Review.
Abstract: http://links.ealert.nature.com/ctt?kn=72&m=32688512&r=MTc2NDQ4MTc5OAS2&b=2&j=NDgxNzMyMTAS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=95&m=32688512&r=MTc2NDQ4MTc5OAS2&b=2&j=NDgxNzMyMTAS1&mt=1&rt=0
Epigenetic control in rheumatoid arthritis synovial fibroblasts
Emmanuel Karouzakis, Renate E. Gay, Steffen Gay and Michel Neidhart
p266 | doi:10.1038/nrrheum.2009.55
Activated synovial fibroblasts have an important role in the destruction
caused in rheumatoid arthritis. The aggressive phenotype of these cells
is influenced by various epigenetic mechanisms, in particular DNA
methylation. Improved understanding of these epigenetic alterations could
inform the development of novel therapies for rheumatoid arthritis.
Abstract: http://links.ealert.nature.com/ctt?kn=76&m=32688512&r=MTc2NDQ4MTc5OAS2&b=2&j=NDgxNzMyMTAS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=129&m=32688512&r=MTc2NDQ4MTc5OAS2&b=2&j=NDgxNzMyMTAS1&mt=1&rt=0
Lupus mesenteric vasculitis can cause acute abdominal pain in patients with
SLE
Ji Hyeon Ju, Jun-Ki Min, Chan-Kwon Jung, Soon Nam Oh, Seung-Ki Kwok,
Kwi Young Kang, Kyung-Su Park, Hyuk-Jae Ko, Chong-Hyeon Yoon, Sung-Hwan Park,
Chul-Soo Cho and Ho-Youn Kim
p273 | doi:10.1038/nrrheum.2009.53
Lupus mesenteric vasculitis is the main cause of acute abdominal pain in
patients with acute gastrointestinal manifestations of systemic lupus
erythematosus. Abdominal CT allows for early and accurate diagnosis of
this painful and potentially life-threatening condition, which enables
implementation of appropriate immunosuppressive therapy and avoidance of
unnecessary surgical intervention.
Abstract: http://links.ealert.nature.com/ctt?kn=107&m=32688512&r=MTc2NDQ4MTc5OAS2&b=2&j=NDgxNzMyMTAS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=27&m=32688512&r=MTc2NDQ4MTc5OAS2&b=2&j=NDgxNzMyMTAS1&mt=1&rt=0
----------------------
CASE STUDY
----------------------
Rapidly fatal HTLV-1-associated T-cell leukemia/lymphoma in a patient with SLE
Ruth D. E. Fritsch-Stork, Roos J. Leguit and Ronald H. W. M. Derksen
p283 | doi:10.1038/nrrheum.2009.49
In this Case Study, the authors describe the unusually fulminant course of
T-cell lymphoma in a 57-year-old Afro-Jamaican woman with an 8-year history
of SLE, from the first presentation of symptoms to the patient's death
shortly after the start of chemotherapy. The patient's ethnic and geographic
background ultimately raised the suspicion of infection with an oncogenic
virus.
Abstract: http://links.ealert.nature.com/ctt?kn=123&m=32688512&r=MTc2NDQ4MTc5OAS2&b=2&j=NDgxNzMyMTAS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=7&m=32688512&r=MTc2NDQ4MTc5OAS2&b=2&j=NDgxNzMyMTAS1&mt=1&rt=0
----------------------
PERSPECTIVES
----------------------
OPINION
Assessing infection risk with biologic agents in RA: methodological challenges
Mark C. Fisher and Jeffrey D. Greenberg
p288 | doi:10.1038/nrrheum.2009.51
Biologic agents are fast becoming a mainstay of treatment for rheumatoid
arthritis. The risk of bacterial and opportunistic infections in patients
treated with these agents remains unknown, however, in part because of
difficulties related to interpretation of relevant trial data.
Abstract: http://links.ealert.nature.com/ctt?kn=112&m=32688512&r=MTc2NDQ4MTc5OAS2&b=2&j=NDgxNzMyMTAS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=48&m=32688512&r=MTc2NDQ4MTc5OAS2&b=2&j=NDgxNzMyMTAS1&mt=1&rt=0
=====================================================================
You have been sent this Table of Contents Alert because you have opted
in to receive it. You can change or discontinue your e-mail alerts at
any time, by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=106&m=32688512&r=MTc2NDQ4MTc5OAS2&b=2&j=NDgxNzMyMTAS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2009 Nature Publishing Group
=====================================================================
